hrp0097p1-446 | Fat, Metabolism and Obesity | ESPE2023

The evolution of diagnosis and care over time in children with Prader-Willi syndrome, born between 2005 and 2021, included in the French database.

Faye Sandy , Molinas Catherine , Brochado Cathy , Valette Marion , Desprez Clémence , Diene Gwenaelle , Arnaud Catherine , Tauber Maithé

Introduction: The French Reference Centre PRADORT set up a national Access® database in 2005 for children diagnosed with Prader-Willi Syndrome (PWS). The medical, socio-demographic and family data of 813 patients were then collected.Method: We aim to analyse the evolution of diagnosis and care over time, according to the birth year of patients by comparing 3 groups (patients born between 2005 to 2009, 2010 to 2014 an...

hrp0097t10 | Section | ESPE2023

Long term effects at 3-4 years of age of early intranasal oxytocin treatment in infants with Prader-Willi syndrome

Valette Marion , Diene Gwenaelle , Glattard Mélanie , Cortadellas Julie , Molinas Catherine , Faye Sandy , Benvegnu Grégoire , Boulanouar Kader , Payoux Pierre , Pierre SALLES Jean , Arnaud Catherine , Cabal-Berthoumieu Sophie , Tauber Maithé

Introduction: The neuropeptide oxytocin (OT) plays an important role in modulating behaviour and social interactions. Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder due to abnormal hypothalamic development including OT dysfunction that involves endocrine, nutritional and behavioural outcomes/features/trajectory. We previously showed in a phase I/II study (NCT02205034) that 18 infants with PWS, less than 6 months of age, who received ...